The biomarkers market revenues were estimated at US$ 59.1 Bn in 2021 and is anticipated to grow at a CAGR of 15.3% from 2022-2032, according to a recently published Fact.MR report. By the end of 2032, the market is expected to reach US$ 278 Bn.
Safety Biomarkers held a market share of nearly 38% and this trend is likely to be continued due to the predicted CAGR of 15.9% in the next ten years. Market growth is expected to be fueled by the growing demand for Safety Biomarkers owing to its demand being driven by high awareness of regular health checks, low usage of medicines, and an increasing population at high risk of developing various diseases such as cancer, cardiovascular and kidney ailments.
development and used to support drug approval. Approval of such drugs has helped grow the U.S. kidney biomarker market. The American Cancer Society reports that 609,640 people have died of cancer in the country. In 2018, 234,030 cases of lung cancer occurred in the United States, and 154,050 people died of lung cancer.
Download Free Sample Copy of This Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=7181
Key Takeaways from the Market Study
- Global biomarkers market is expected to reach a market size of US$ 278 Bn by 2032.
- In 2022, North America to contribute more than 30% market revenue.
- Safety Biomarkers demand accounted for 38% of the market revenue in 2022
- Cancer detection show the highest potential for growth in the disease type segment. It is expected to grow at a rate of about 17.1% from 2022- 2032.
- S., the key market is expected to hold the prominent market share and grow at a CAGR of 16.7% during 2022 – 2032.
How Biomarkers are Being Effectively used for Diagnostics?
The diagnostic biomarker market has found that breakthroughs in diagnostic tools provide accurate and consistent results in early diagnosis compared to traditional diagnostic tools. Biomarkers are integrated with advanced data management technology and key imaging. Therefore, it meets the needs of early detection and meets the expectations of the market.
Medical practice requires an accurate diagnosis of illness or conditions. Diagnostic biomarkers critically determine whether a patient has a particular medical condition that may require treatment, or whether an individual needs to be enrolled in a clinical trial investigating a particular disease. As is increasingly recognized, many diseases have subtypes that have significantly different prognosis or response to a particular treatment.
The U.S. dominated the market in 2021 with a market share of over 55%. This is due to increased R & D investment and the local presence of global players.
Over the last decade, the number of USFDA-approved drug labels containing molecular biomarker information has increased significantly. In addition, almost all pharmaceutical companies have developed molecular biomarker programs through partnerships or other ventures.
Molecular biomarkers are identified and validated in drug
Get Customization on this Report for Specific Research Solutions – https://www.factmr.com/connectus/sample?flag=RC&rep_id=7181
Competitive Landscape
A number of regional and global players operate in this market. These companies compete based on the innovation of their products, their quality, their brand reputation, and their market presence in order to sell their products through various industries. A variety of strategies are being employed by companies to remain competitive.
- In May 2021, the Cerascreen KRAS RGQ PCR kit, the first FDA-approved diagnostic tissue sample to identify KRAS G12C mutations in QIAGEN NV NSCLC tumors and expand precision medical options for lung cancer, was launched.
- In April 2021, F. Hoffmann La Roche Ltd. Introduced two cardiac biomarker tests, the sensitive cardiac troponin T (cTnThs) and the N-terminal pro-brain natriuretic peptide test (NTproBNP). These gold standard biomarkers support the management of cardiovascular disease and may help physicians diagnose heart attacks and better manage heart failure.
- In July 2020, Thermo Fisher Scientific signed a contract with to expand the use of the targeted Oncomin-Dx test in patients with non-small cell lung cancer (NSCLC) and accelerate local biomarker testing.
- In January 2020, Merck KGaA opened a non-profit high-tech capacity development center in Chandigarh, India, in collaboration with the Institute for Microbial Technology (CSIRIMTECH) of the Scientific and Industrial Research Council. The center is has single-molecule biomarker detection, genome editing, and other technologies to help onsite students gain life science skills.
Key Companies Profiled
- Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Epigenetics AG
- General Electric
- Johnson & Johnson Services, Inc.
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Siemens Healthineers AG
- Qiagen
For In-Depth Competitive Analysis, Buy Now – https://www.factmr.com/checkout/7181
Market Segments Covered in Biomarkers Industry Analysis
- By Disease Type :
- Cardiovascular Diseases
- Cancer
- Neurological Diseases
- Immunological Diseases
- Other Disease Types
- By Type :
- Safety
- Efficacy
- Validation
- By Application :
- Diagnostics
- Drug Discovery & Development
- Personalized Medicines
- Other Applications
- By Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- MEA
Check Out More Related Studies Published By Fact.MR Research:
Cancer Profiling Market: The global cancer profiling market is expected to yield significant gains across 2021, as preference for precision-based medicine and high quality oncology care acquires increasing traction. With global cancer burden slated to proliferate, patients and medical practitioners alike are scrambling to offer highly efficacious and long-lasting cancer diagnostics, prompting the entry of numerous service providers.
Cancer RNA Expression Market: Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease.
Cancer Genomic Testing Market: Cancer genomic testing is a newer field of genetics which is used to diagnose the different type of cancer. Cancer genomic testing is completely different from genetic testing, because during genomic testing all of patient gene is being tested. Alteration or mutation of genes is the key cancer causing factor. During the cancer genomic testing, the alteration or mutation of gene is being tested.
Cancer Therapeutics Market: The global cancer therapeutics market is estimated at USD 12.1 Billion in 2022 and is forecast to surpass USD 28.3 Billion by 2032, growing at a CAGR of 8.8% from 2022 to 2032. The global cancer therapeutics market is likely to create an absolute dollar opportunity of USD 16.2 Billion by the end of 2032. The global cancer therapeutics market holds ~12% of the global therapeutics market.
Cancer Immunotherapy Market: The cancer immunotherapy market garnered US$ 119.4 Bn by 2021, according to Fact.MR- a market research and intelligence provider. The market is expected to exceed US$ 310 Bn by registering a staggering CAGR of 10% by the end of the assessment period 2021-2031.
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com